Lerner Neil purchased $3K of CMPX
Lerner Neil (Chief Accounting Officer) purchased 2,500 shares of Compass Therapeutics, Inc. (CMPX) at $1.14 on 2026-09-24.
How this was made
The 30-second read
Why it matters
The disclosed purchase is modest and unlikely to move the stock, but it adds to the cumulative insider activity record.
Market read
Routine insider purchase with limited trading relevance.
What to watch
Potential upcoming corporate actions or clinical milestones not reflected in this filing.
Background
Form 4 filings provide the first public disclosure of insider transactions, offering transparency into insider sentiment.
Ticker impact
Chief Accounting Officer Lerner Neil bought 2,500 shares of Compass Therapeutics at $1.14 each, a $2,850 purchase disclosed on Form 4.
Minimal, likely no immediate move.
The transaction is modest relative to total float and typical insider activity; traders should not expect a material price reaction.
Market effects
None; the purchase does not affect the broader biotech sector.
None; limited to U.S. market participants.
None
Counterpoint
Even a small insider buy can precede a larger strategic move; monitor for future filings.
Key entities
- companyCompass Therapeutics, Inc.
Biotech firm developing therapies for rare diseases.
- personLerner Neil
Chief Accounting Officer of Compass Therapeutics.
